The Memo: YoungHeartValve Building a Truly Durable, Anticoagulation-Free TAVR
Under the direction of Co-Founder and CTO Lakshmi (Prasad) Dasi, PhD, YoungHeartValve is developing a fully synthetic, polymer-based transcatheter aortic valve designed to deliver lifelong durability without the need for chronic anticoagulation.
Significant additional funding secured for further development
This unique trans-catheter valve technology features novel, molecular-level, engineered polymeric leaflets with natural biomolecules, making it durable and highly hydrophilic with proven resistance to blood clotting and calcification. In addition to freedom from reliance on animal tissue, the technology promises ease of mass production. “Our technology will provide both next-level durability and unprecedented hemocompatibility, compared […]
Young Heart Valve Awarded Funding Through SBIR Phase 1
YoungHeartValve has received $2.8 million in additional Small Business Innovation Research (SBIR) grant funding from the National Institutes of Health (NIH) to further advance development of its next-generation transcatheter aortic valve platform. This award brings the company’s total non-dilutive funding to $6.5 million, supporting continued preclinical testing and development of the company’s flagship technology, the Transcatheter […]